FMR1 and fragile X syndrome: This pathology is strictly associated with reduced cAMP levels in mice and the use of BPN14770, a potent PDE4D allosteric inhibitor [171] in the animal model of FXS (Fmr1 KO), afforded positive effects, such as hyperactivity decrease and behaviour improvement [172].